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Abstract
Background: Hepatocellular carcinoma (HCC) is an aggressive cancer, and is the third leading
cause of cancer death worldwide. Standard therapy is ineffective partly because HCC is intrinsically
resistant to conventional chemotherapy. Its poor prognosis and limited treatment options make it
critical to develop novel and selective chemotherapeutic agents. Since the Wnt/β-catenin pathway
is essential in HCC carcinogenesis, we studied the inhibition of Wnt-1-mediated signaling as a
potential molecular target in HCC.
Results: We demonstrated that Wnt-1 is highly expressed in human hepatoma cell lines and a
subgroup of human HCC tissues compared to paired adjacent non-tumor tissues. An anti-Wnt-1
antibody dose-dependently decreased viability and proliferation of Huh7 and Hep40 cells over-
expressing Wnt-1 and harboring wild type β-catenin, but did not affect normal hepatocytes with
undetectable Wnt-1 expression. Apoptosis was also observed in Huh7 and Hep40 cells after
treatment with anti-Wnt-1 antibody. In these two cell lines, the anti-Wnt-1 antibody decreased β-
catenin/Tcf4 transcriptional activities, which were associated with down-regulation of the
endogenous β-catenin/Tcf4 target genes c-Myc, cyclin D1, and survivin. Intratumoral injection of
anti-Wnt-1 antibody suppressed in vivo tumor growth in a Huh7 xenograft model, which was also
associated with apoptosis and reduced c-Myc, cyclin D1, and survivin expressions.
Conclusion: Our results suggest that Wnt-1 is a survival factor for HCC cells, and that the
blockade of Wnt-1-mediated signaling may offer a potential pathway-specific therapeutic strategy
for the treatment of a subgroup of HCC that over-expresses Wnt-1.
Background
Hepatocellular carcinoma (HCC) is the primary form of
human adult liver cancer. It is the fifth most common can-
cer worldwide, with about one million new cases diag-
nosed annually, and almost an equal number of deaths. It
is predominant in China, most parts of South East Asia,
and South Africa, where hepatitis B virus (HBV) infection
is endemic [1]. The last decade has seen no major
advances in the treatment of HCC. Approximately 10-
25% of HCC patients are candidates for surgical resection
and liver transplantation; the majority of patients have
limited treatment options due to the lack of effective
chemotherapy against this intrinsically resistant tumor [2-
4]. New pharmacological interventions that offer even
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modest improvements in efficacy and disease outcome are
eagerly sought.
The Wnt/β-catenin pathway plays an important role in
embryogenesis and carcinogenesis [5,6]. Secreted proteins
of the Wnt family bind to specific Frizzled (FZD) receptors
on the surface of target cells to activate distinct intracellu-
lar pathways, resulting in the accumulation and nuclear
localization of the β-catenin protein. Nuclear β-catenin
binds to T-cell factor 4 (Tcf4) to drive activation of specific
target genes including cyclin D1, c-Myc, and survivin,
which have been characterized to be critical for cancer
development [7-9]. Clinical studies have reported that
abnormal activation of Wnt/β-catenin pathway is fre-
quently involved in hepatocarcinogenesis. About 33-67%
of HCC tissues show accumulation of β-catenin in the
cytoplasm and nucleus, whereas no accumulation was
observed in the corresponding normal tissues [10,11]. In
addition, FZD7, a receptor for Wnt ligands, was reported
to be involved in HCC development and progression
[12,13].
The Wnt-1 ligand has been reported to be abnormally
expressed in a variety of human cancers including HCC
[14,15]. In HCC, proteomics results suggested that
enhanced Wnt-1 expression associated with NF-kB might
be an important mechanism underlying hepatocarcino-
genesis [16]. Moreover, transgenic mice model suggested
that high expression of Wnt-1 could be the major cause
for nuclear accumulation of β-catenin, which subse-
quently contributes to c-myc/E2F1-driven hepatocarcino-
genesis [17]. Elevated levels of tumor Wnt-1 protein in
HBV- and hepatitis C virus (HCV)-related HCC has
recently been shown to be a prognostic indicator of HCC
recurrence after surgical resection [18]. Because of the
functional importance of Wnt-1 in HCC development
and progression, we investigated the anti-tumor effects of
blocking Wnt-1 mediated signaling through the Wnt/β-
catenin pathway in human HCC. By using a polyclonal
anti-Wnt-1 antibody, we studied the effects of Wnt-1
blockade on HCC cell growth in vitro and in vivo, and the
effects on Wnt/β-catenin mediated transcriptional activity
in HCC cells.
Results
Over-expression of Wnt-1 protein in HCC tissue specimens 
and cell lines
To confirm the expression of Wnt-1 protein in HCC, we
used the anti-Wnt-1 antibody to detect its expression in
seven pairs of HCC tissues and their corresponding adja-
cent non-tumor tissues. These tissues were obtained with
informed consent from seven HCC patients undergoing
surgical resection at Stanford Hospital. Expression of Wnt-
1 in HCC tissues was at least 1.5 fold greater than in
paired non-tumor tissues in four out of the seven tissue
pairs (Fig. 1A). Despite the small sample size, our data
closely reflect that reported recently by Lee et al [18], who
observed that 26 of 63 HCC patients had tumor/non-
tumor Wnt-1 expression ratio of ≥ 1.5, whereas 37 of 63
had a ratio of <1.5. Wnt-1 protein expression was in gen-
eral higher in human HCC cell lines (Huh7, Hep40, and
HepG2), but was undetectable in normal hepatocytes cul-
tured from three different donors (Hu4122, Hu4074,
Hu0910) (Fig. 1B). In general, our observations corrobo-
rate with published reports that Wnt-1 is upregulated in
HBV- and HCV-related HCC tissues and cell lines [16,19].
Anti-Wnt-1 antibody decreases cell proliferation and 
induces apoptosis in HCC cell lines
The over-expression of Wnt-1 in HCC implies that Wnt-1
may be involved in hepatocellular carcinogenesis, and
may be critical for the growth of HCC cells. We therefore
further studied its potential as a therapeutic target for
HCC treatment. After 72 hr exposure, the anti-Wnt-1 anti-
body dose-dependently decreased cell viability in Huh7
and Hep40 cells, but not in HepG2 cells and normal
hepatocytes from three different donors (Fig. 2A and 2B).
The lack of activity against HepG2 cells may be due to the
presence of truncated β-catenin (with loss of the GSK-3β
regulatory site) in these cells, which therefore escapes reg-
ulation by upstream events [20]. As a specificity control,
we examined the effect on cell proliferation of overnight
pre-incubation of the anti-Wnt-1 antibody with its spe-
cific blocking peptide (at 20-fold concentration over the
antibody). The anti-proliferative effect of anti-Wnt-1 anti-
body on Huh7 and Hep40 cells were blocked by pre-treat-
ment with the blocking peptide (Fig. 2C), suggesting that
the anti-Wnt-1 antibody can bind specifically to the native
form of the Wnt-1 protein in these cells, and that the
observed anti-proliferative effect is mediated by inhibi-
tion of Wnt-1 protein functions by the anti-Wnt-1 anti-
body.
Using the TUNEL assay, induction of apoptosis was
observed at an effective concentration of anti-Wnt-1 anti-
body in Huh7 (Fig. 2D) and Hep40 cells (data not
shown). Most of the dead cells were stained as apoptotic
cells when treated with 10 μg/ml of the anti-Wnt-1 anti-
body for 72 hrs (Fig. 2D). Overnight pretreatment with
the Wnt-1 specific blocking peptide (20-fold over anti-
body) markedly reduced the number of apoptotic cells
after treatment with anti-Wnt-1 antibody (Fig. 2D). Our
data suggest that cell apoptosis was specifically induced
by the anti-Wnt-1 antibody in Huh7 and Hep40 cells.
Anti-Wnt-1 antibody inhibits Wnt/β-catenin signaling and 
suppresses the expression of downstream oncoproteins
To determine if the effects of anti-Wnt-1 antibody on
Huh7 and Hep40 cells were related to inhibition of Wnt/
β-catenin signaling, we used the Tcf4 transcriptionalMolecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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reporter (TOP/FOP FLASH) assay to detect β-catenin/Tcf4
transcriptional activity in these cell lines after 48 hr treat-
ment with the antibody (2 μg/ml). The anti-Wnt-1 anti-
body dose-dependently decreased β-catenin/Tcf4
transcriptional activity (Fig. 3A), and also reduced the
accumulation of β-catenin in the nuclei of Huh7 and
Hep40 cells (Fig. 3B). No effects on β-catenin/Tcf4 tran-
scriptional activity or β-catenin accumulation were
observed in HepG2 cells (data not shown). Control IgG
had no effect on transcriptional activity or nuclear β-cat-
enin levels. Consistent with these observations, the
endogenous levels of β-catenin/Tcf4 regulated proteins (c-
Myc, cyclin D1, and survivin) were reduced after 48 hr
treatment with the anti-Wnt-1 antibody (2 μg/ml), but
not after treatment with control IgG (Fig. 3C). These three
proteins are commonly known to be over-expressed in
HCC tissues [7-9], and our results indicate that their
expression is regulated by Wnt-1-mediated β-catenin/Tcf4
signaling.
Anti-Wnt-1 antibody inhibits growth of HCC xenografts in 
nude mice
We next studied the in vivo effects of the anti-Wnt-1 anti-
body on tumor growth in a HCC xenograft model in nude
mice. Huh7 cells were injected subcutaneously into nude
mice to initiate tumor formation. When established
xenografts were palpable (approximately after 14 days),
mice were intratumorally injected with the anti-Wnt-1
antibody (50 μg/kg), and PBS as control (n = 5 in each
group) once weekly. Compared with PBS control, the
anti-Wnt-1 antibody effectively inhibited tumor growth in
vivo (ANOVA, P < 0.05, compared with PBS control at the
beginning of the third week) (Fig. 4A). Tumor tissues were
harvested after sacrificing the mice at the end of the treat-
ment period, and were analyzed via  TUNEL staining.
Apoptotic cells were detected in tumors treated with the
anti-Wnt-1 antibody, but not in the control group (Fig.
4B). When immunostained with anti-c-Myc, cyclin D1,
and survivin antibodies, tumor tissues that had been
treated with anti-Wnt-1 antibody showed reduced c-Myc,
cyclin D1, and survivin expressions (Fig. 4C and 4D).
These results are consistent with our in vitro observations
that the antibody inhibited β-catenin/Tcf4 mediated tran-
scriptional activity.
Discussion
The Wnt gene family encodes at least 19 secreted factors
involved in cell growth, differentiation, embryogenesis
and oncogenesis [21]. The expression of the Wnt-1 ligand
in mammalian cells results in the accumulation of steady-
state levels of cytosolic and nuclear β-catenin [22], which
contributes to the development of many types of cancers
[6]. Recently, several Wnt proteins, including Wnt-1, have
been shown to be over-expressed in HCC tumor com-
pared with the corresponding non-tumor tissue from hep-
atitis B and C-infected patients [16]. Moreover, in vitro
models have been used to study how the over-expression
of Wnt-1 is involved in HCV-induced Huh-7 cell prolifer-
ation and HBV X protein-induced β-catenin/Tcf4 tran-
scription activation [19,23]. Consistent with these recent
findings, we have shown that Wnt-1 protein is over-
expressed in HCC tissues and cell lines, but not in adja-
cent non-tumor liver tissues or cultured normal hepato-
cytes. Our in vitro and in vivo data further support the use
of an anti-Wnt-1 antibody as a new treatment option for
HCC, since it blocks Wnt-1 mediated β-catenin/Tcf4 tran-
scription, which in turn leads to reduced proliferation,
enhanced apoptosis, and down-regulation of important
downstream target oncoproteins in HCC.
Wnt-1-mediated β-catenin/Tcf4 transcription is an impor-
tant cellular survival pathway that promotes cell prolifer-
ation, cell cycle progression, and cellular transformation
[24]. Because Wnt proteins are indispensible for cancer
cell growth and survival, we studied the potential anti-
tumor effect of anti-Wnt-1 antibody in HCC cells. Com-
pared to the control goat IgG, anti-Wnt-1 antibody
decreased proliferation and induced apoptosis in Huh7
and Hep40 cell lines over-expressing Wnt-1 protein (and
with wild type β-catenin). These effects were blocked by
pre-treatment with the Wnt-1 blocking peptide, demon-
strating that they were mediated by specific binding of the
anti-Wnt-1 antibody to the native form of Wnt-1 protein
Expression of Wnt-1 protein in human HCC tumors and cell  lines Figure 1
Expression of Wnt-1 protein in human HCC tumors 
and cell lines. A). Western blot detection of Wnt-1 expres-
sion in human HCC tumor tissues (T) and the corresponding 
adjacent non-tumor liver tissues (N). B). Western blot detec-
tion of Wnt-1 expression in HCC cell lines (HepG2, Huh7, 
and Hep40), and normal hepatocytes from three donors 
(Hu0910, Hu4122, Hu4074). The immunoblots were quanti-
fied by densitometry and the intensities normalized with 
those of β-actin and given beneath each band.Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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In vitro anti-proliferative and apoptotic effects of anti-Wnt-1 antibody on human HCC cell lines Figure 2
In vitro anti-proliferative and apoptotic effects of anti-Wnt-1 antibody on human HCC cell lines. A). Cell viability 
assays based on cellular ATP content were used to determine the effect of anti-Wnt-1 antibody on three human HCC cell lines 
and normal hepatocytes from three donors following 72 hr of antibody treatment. Relative ATP activity is proportional to the 
number of viable cells. Three independent experiments were done, each in triplicates. B). Phase-contrast microscopic examina-
tion of the effect of different concentrations of anti-Wnt-1 antibody on HCC cell line Huh7 and normal hepatocytes Hu0910. 
C). Pre-treatment with Wnt-1 specific blocking peptide abolished the anti-proliferative effect of anti-Wnt-1 antibody in Huh7 
and Hep40 cells. Results are presented as mean ± SD (error bars). D). Anti-Wnt-1 antibody induced apoptosis in Huh7 cells. 
Huh7 cells were treated with anti-Wnt-1 antibody (10 μg/ml) with or without blocking peptide pre-treatment. After 72 hr 
incubation, cells were washed, fixed, and stained with TUNEL and PI as described under Materials and Methods to detect for 
apoptotic cells. Fluorescence labeling was visualized and photographed at 100× magnification.Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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in these cells. However, the anti-Wnt-1 antibody had no
effect on HepG2 cells (with high expression of Wnt-1 pro-
tein, but harbors both wild type and truncated β-catenin)
[25], and normal hepatocytes from three different donors
(with undetectable Wnt-1 expression). Truncation of β-
catenin in HepG2 cells is caused by a large gene deletion
(loss of amino acids 20-140) involving loss of the GSK-3β
regulatory site, which leads to failure of the protein to be
phosphorylated by GSK3β. Thus, β-catenin constitutively
accumulates in the nucleus of HepG2 cells and may
escape regulation by the anti-Wnt-1 antibody acting
upstream. Similar results were observed by Shih et al. [20],
who found that the restoration of secreted frizzled-related
proteins (SFRPs; extracellular signaling glycoproteins that
antagonize Wnt signaling) attenuated Wnt signaling in
Huh6 cells (with a β-catenin point mutation), but not in
HepG2 cells with truncated β-catenin. However, as the
incidence of similar β-catenin truncation is low in human
HCC (only 1 out of 26 HCC patients had β-catenin trun-
cation) [25], the anti-Wnt-1 antibody has potential wide
applicability in the majority of HCC patients.
Activation of β-catenin/Tcf4 transcription by Wnt-1 has
been reported to be responsible for Wnt-1-mediated cell
survival [24]. Longo et al. [26] also demonstrated that
Wnt-1 caused 3T3-L1 cells to resist apoptosis in response
to serum deprivation through inhibition of GSK-3β activ-
ity and stabilization of β-catenin. Conversely, blockade of
Wnt-1 signaling using Wnt-1 antibodies have been
reported to induce apoptosis in a variety of human cancer
cell lines, including non small cell lung cancer, breast can-
cer, colorectal cancer mesothelioma, and sarcoma
[27,28]. Treatment with antibodies against Wnt-1 and
Wnt-10b also inhibited proliferation and induced apop-
tosis in head and neck squamous cell carcinoma
(HNSCC) cells [29]. Consistently, we observed that anti-
Wnt-1 antibody inhibited β-catenin/Tcf4 transcriptional
activity as measured using the TOPFLASH and FOPFLASH
reporter assay, and also led to accumulation of β-catenin
in the nuclei of Huh7 and Hep40 cells. This implies that
anti-Wnt-1 antibody acts via the canonical Wnt signaling
cascade to induce apoptosis in both cell lines.
The canonical Wnt signaling pathway, via the β-catenin/
Tcf4 complex, regulates the expression of multiple onco-
proteins, including c-Myc, cyclin D1, and survivin in HCC
[7-9]. In the Huh7 and Hep40 cells in vitro, anti-Wnt-1
antibody markedly reduced the expression of c-Myc, cyc-
lin D1, and survivin, consistent with its ability to inhibit
β-catenin/Tcf4 transcriptional activity. One of the most
common oncoproteins associated with the pathogenesis
of HCC is c-Myc [8]; its elevated expression in mice mod-
els was found to initiate and promote liver tumor growth
[30,31]. The deletion of c-Myc alone in a mouse liver
tumor model efficiently suppressed tumor growth in vivo
[32]. Cyclin D1 was reported to be significantly elevated
in HCC compared with surrounding cirrhotic tissues [9].
In HCC cells, cyclin D1-related kinase activity was accom-
panied by up-regulation of Cdk4 activity, and phosphor-
ylated and activated pRB, which promote G1 to S phase
transition [9]. Additionally, the over-expression of sur-
vivin promotes proliferation in HCC by initiating cell
cycle entry (a decrease in the G0/G1 phase and an increase
in the S phase) [7]. Its inhibition led to cell cycle arrest, an
effect which can augment the sensitivity of HCC tumor
cells to cytotoxic drugs [33]. These three oncoproteins (c-
Myc, cyclin D1, and survivin) have important functional
roles in the development of HCC, and the ability to regu-
late them simultaneously offers a powerful way to inter-
vene with HCC progression.
Conclusion
In conclusion, our data suggest that targeting Wnt-1 medi-
ated Wnt/β-catenin signaling (which is frequently acti-
vated in HCC) may be a feasible and novel therapeutic
option. The specific and effective blockade of this signal-
ing pathway using an anti-Wnt-1 antibody inhibited HCC
cell proliferation and induced apoptosis in vitro. Corre-
spondingly, suppression of HCC tumor xenograft growth
and apoptosis were also observed in vivo. The ability of the
anti-Wnt-1 antibody to down-regulate the expression of
downstream targets of Wnt/β-catenin signaling, including
c-Myc, cyclin D1, and survivin, suggest that a broad spec-
trum of cellular mechanisms can be triggered in concert to
halt HCC tumor growth. Lastly, since Wnt-1 is often
deregulated in HCC with underlying HBV or HCV (the
main risks factors of HCC), we propose that interference
with Wnt-1 mediated signaling offers a potent and selec-
tive therapeutic strategy for the clinical management of a
substantial proportion of HCC patients with Wnt-1 over-
expression.
Material and methods
Tissue samples and cell lines
Paired (HCC and adjacent non-tumor liver) tissues were
obtained from seven patients who underwent liver resec-
tion for HCC at Stanford Hospital, Stanford University,
California. This study was approved by the Institutional
Review Board for the use of human subjects in medical
research, and informed consent was obtained from
patients prior to liver resection. Ages ranged from 44 to 73
years. All patients were men with HBV-related HCC.
Human hepatoma cell lines, HepG2, Hep40, and Huh7
were maintained in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 μg/mL penicillin and 100 μg/mL streptomycin.
All media and supplements were from Invitrogen
(Carlsbad, CA). Cells were maintained at 37°C in a
humidified atmosphere with 5% CO2.Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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Anti-Wnt-1 antibody inhibited β-catenin/Tcf4 transcriptional activity Figure 3
Anti-Wnt-1 antibody inhibited β-catenin/Tcf4 transcriptional activity. A). Tcf4 reporter assay of Tcf-dependent tran-
scriptional activity in Huh7 and Hep40 cell lines. Huh7 and Hep40 cells were co-transfected with plasmid encoding β-galactosi-
dase (a control for transfection efficiency) and either the pTOPFLASH or pFOPFLASH reporters. Cells were incubated with 
anti-Wnt-1 antibody or control IgG (2 μg/ml) and harvested after 48 hr to measure luciferase and β-galactosidase activities. 
Reporter gene activation is expressed in terms of relative light units (RLU) detected in pTOPFLASH or pFOPFLASH trans-
fected cells and normalized for β-galactosidase activity. The results are expressed as mean ± SD (error bars). Experiments 
were performed in triplicates; P < 0.05. B). Anti-Wnt-1 antibody decreased nuclear β-catenin accumulation in Huh7 and Hep40 
cells. Histone 3 was used as the loading control. C). The effect of anti-Wnt-1 antibody on the expression of β-catenin/Tcf4 tar-
get genes c-Myc, cyclin D1, and survivin. Huh7 and Hep40 cells were incubated for 48 hr with anti-Wnt-1 antibody (2 μg/ml) 
and c-Myc, cyclin D1, survivin and β-actin (loading control) levels were determined by Western blotting using specific antibod-
ies.Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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Anti-Wnt-1 antibody and blocking peptide
The anti-Wnt-1 goat polyclonal antibody, the correspond-
ing control goat IgG, and the Wnt-1 specific blocking pep-
tide were from Santa Cruz Biotechnology (Santa Cruz,
CA). Antibodies were concentrated using Microcon-30
ultrafugation devices (Millipore Corporation, Bedford,
MA) before being added to cells. The blocking peptide was
purified by dialysis using a Slide-A-Lyzer Dialysis Cassette
with a 2,000 MWCO (Promega, Madison, WI). For block-
ing experiments, blocking peptide was pre-incubated with
cells overnight, at 20-fold concentration over the anti-
Wnt-1 antibody.
Primary culture of hepatocytes
Cryopreserved human hepatocytes, collagen hand-coated
96-well plates, CHRM Thawing Medium, Cell Plating
Medium, and Cell Maintenance Medium were received
from CellzDirect/Invitrogen (Durham, NC). Characteris-
tics of the three hepatocyte lots are shown in Table 1. Cry-
opreserved human hepatocytes were thawed based upon
CellzDirect's standard method: hepatocytes were thawed
at 37°C, then poured into pre-warmed 37°C CHRM
Thawing Medium at a ratio of one vial (approximately 5
million cells)/50 ml in a conical tube. The cells were then
centrifuged at 100g for 10 min and resuspended to 0.75 ×
106 cells/mL in Plating Medium. Cell viability was deter-
mined by trypan blue exclusion. Hepatocytes were then
plated in collagen-coated 96-well plates at a density of 3 ×
104 cells/well in a volume of 100 μl/well. After 5 h of incu-
bation at 37°C, Plating Media was replaced with serum-
free Maintenance Media at 100 μl/well, and incubated
overnight for cytotoxicity assay as described below.
Cell viability and proliferation assays
Hepatoma cells were seeded in 96-well plates at 3 × 103
cells/well, and incubated overnight at 37°C prior to addi-
tion of anti-Wnt-1 antibody. Anti-Wnt-1 antibody and
control IgG were added at desired final concentrations
(range from 0-20 μg/ml), and further incubated for 72 h
before cell viability and proliferation were assessed using
CellTiter-Glo Luminescent Cell Viability Assay (Promega,
Madison, WI) or .CellTiter 96® AQueous One Solution
Cell Proliferation Assay (Promega, Madison, WI) respec-
tively, according to the manufacturer's instructions.
Briefly, for the .CellTiter-Glo assay, the assay regents (a
combination of detergent and luciferase-based enzyme)
were directly added to cultured cells, resulting in cell lysis
and the production of a bioluminescent signal propor-
tional to the amount of ATP present. Luciferase activity
was measured on a luminometer (Berthold LB-96V) and
values were normalized to the ATP activity and compared
with their respective PBS control value, which was set at
100. Three independent experiments were done, each in
triplicates. For proliferation assay, optical density (OD)
was read at 490 nm using a SAFIRE microplate reader
(TECAN, Research Triangle Park). The background value
(mean OD values from wells with only the AQueous One
Solution) was subtracted from all data. Three independ-
ent experiments were done, each in triplicates.
Luciferase reporter gene assay
β-catenin/Tcf4 transcriptional reporter gene assays were
performed using TCF/Luc reporter constructs, wild type
pTOPFLASH, and mutant pFOPFLASH, which were gener-
ously provided by B Vogelstein (John Hopkins Oncology
Center, Baltimore, MD, USA) [34]. Cells were seeded at 3
× 104 cells/well into 24-well plates and incubated for 24 hr
prior to transfection with wild type pTOPFLASH or
mutant pFOPFLASH (0.7 μg) using Lipofectamine 2000
(Invitrogen, Carslbad, CA) according to the manufac-
turer's instructions. The β-galactosidase (β-gal) expression
vector (0.1 μg) was added to each transfection system to
normalize the transfection efficiency. After 4 hr, medium
containing transfection regent was replaced with new cul-
ture medium containing the anti-Wnt-1 antibody or con-
trol IgG (2 μg/ml). After 48 hr, cells were lysed in 100 μl
of lysis buffer, and 20 μl aliquots were assayed for luci-
ferase activity using the Promega Luciferase assay system
or for β-gal activity using the Promega β-gal assay system.
Relative light units (RLU) were measured and normalized
for transfection efficiency using β-gal activity. Final RLU
representing Tcf4 transcriptional activity were calculated
by subtracting normalized levels obtained with pFOP-
FLASH from those obtained with pTOPFLASH.
Apoptosis Analysis
TUNEL (Terminal dUTP nick-end labeling) assays
(Promega, Madison, WI) were performed according to the
manufacturer's protocol. Briefly, Huh7 or Hep40 cells
were seeded in 8-chamber BD tissue culture slides (BD
Bioscience Labware, Bedmord, MA) at 10% confluency.
Control IgG or anti-Wnt-1 antibody was added to the
medium at final concentration of 10 μg/ml each. After 72
hr incubation, cells were washed twice with PBS, and then
fixed in 4% paraformaldehyde for 25 min. Fixed cells were
washed twice in PBS with 0.1% Triton X-100, and then
incubated with TUNEL reaction mixture for 60 min at
37°C. After washing with 2xSSC, slides were immersed in
PBS with 1 μg/ml Propidium Iodide (PI) for 5 min in the
dark and then washed with PBS. Fluorescence labeling
was visualized and photographed (100× magnification)
with a fluorescence microscope (Nikon Eclipse 80i, Nikon
Corporation, Tokyo, Japan) and with a digital camera
(Nikon DXM1200f, Nikon Corporation, Tokyo, Japan).
For TUNEL staining of the tumor xenografts, 4-μm tissue
sections of tumor xenografts from in vivo experiments
were stained using the ApopTag Peroxidase in Situ Oligo
Ligation Apoptosis Detection Kit (Chemicon Interna-
tional, Temecula, CA) according to the manufacturer's
protocol.Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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Anti-Wnt-1 antibody suppressed tumor xenograft growth in vivo Figure 4
Anti-Wnt-1 antibody suppressed tumor xenograft growth in vivo. A). Nude mice bearing Huh7 tumor xenografts 
were treated with anti-Wnt-1 antibody (dose: 50 μg/kg; once a week), or with PBS as a control (n = 5 in each group). Signifi-
cant differences in the tumor volumes between anti-Wnt-1 antibody-treated and PBS control groups were observed at the 
beginning of the third week after initiation of treatment (P < 0.05). B). TUNEL staining of the xenograft specimens removed 
from controls and mice treated with anti-Wnt-1 antibody (200× magnification). Red arrows indicate the positively stained 
apoptotic cells. C). Xenograft specimens removed from controls and mice treated with anti-Wnt-1 antibody were immunos-
tained to detect expression of c-Myc, cyclin D1, and survivin (400× magnification). The number of positively stained cells were 
counted from three randomly selected areas and the values represent mean ± SD (error bars).Molecular Cancer 2009, 8:76 http://www.molecular-cancer.com/content/8/1/76
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Western blotting and antibodies
Huh7 or Hep40 cells were seeded at 50% confluency in 6-
well plates and incubated at 37°C overnight. Cells were
then treated with PBS, control IgG, or anti-Wnt-1 anti-
body (2 μg/ml) for 48 hr. Cell monolayers were washed
twice with PBS and then lysed in RIPA extraction buffer.
For nuclear β-catenin immunodetection, nuclear extracts
were prepared with a NE-PER Nuclear and Cytoplasmic
Extraction Kit (Pierce, Rockford, IL). Equal amounts of
protein (20 μg) were resolved by SDS-PAGE and Western
blots were performed by using the primary antibodies to
c-Myc (1:500, Cat. 551101, BD Pharmingen, San Diego,
CA), cyclin D1 (1:1000, Cat. ab6152, Abcam, Cambridge,
MA),, survivin (1:1000, Cat. NB500-201H, Novas Biolog-
icals, Littleton, CO), β-catenin (1:500; Cat. SC-7963,
Santa Cruz Biotechnology, Santa Cruz, CA), Histone H3
(1:10000, Cat. Ab21054, Abcam, Cambridge, MA) or β-
actin (1:10000, Cat.A3854, Sigma-Aldrich, MO). Second-
ary antibodies (anti-mouse, Cat.SC-2005, and anti-rabbit,
Cat.SC-2004) conjugated with horseradish peroxidase
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Western blots were analyzed by ImageJ soft-
ware, and signal intensities normalized to β-actin.
Xenografts in Nude Mice
Nude mice (ATHYMIC NU/NU; Harlan Sprague-Dawley,
Indianapolis, IN) at age 4-6 weeks with a body weight of
18 to 25 g were used for the experiments. Mice were
injected subcutaneously at the dorsal region with 5 × 106/
150 μl viable Huh7 cells. After two weeks, when tumors
reached approximately 0.4-0.5 cm in diameter, mice were
randomized into groups (n = 5) to be intratumorally
injected with 100 μl of PBS or anti-Wnt-1 antibody at the
dose of 50 μg/kg once a week. Tumor size was measured
with digital calipers every three days and was calculated
using the formula π/6 × larger diameter × [smaller diame-
ter]2. Mice were sacrificed at the end of the treatment
period, and xenografts harvested.
Immunohistochemical Analysis
Immunoperoxidase stain of tumor xenografts was per-
formed on acetone-fixed 4-μm tissue sections. Briefly, sec-
tions were incubated with monoclonal mouse anti-
human c-Myc (1:200, Cat. 551101, BD Pharmingen, San
Diego, CA), cyclin D1 (1:250, Cat. ab6152, Abcam, Cam-
bridge, MA), or survivin (1:500, Cat. NB500-201H, Novas
Biologicals, Littleton, CO) and then washed with PBS.
Subsequent procedures were performed using Dakocyto-
mation Envision System-HRP mouse system (DakoCyto-
mation Inc, CA, USA) according to the manufacturer's
protocol. We observed c-Myc staining in the cytoplasm
and nuclei, and cyclin D1 and survivin staining in the cyp-
toplasm, consistent with other reports in HCC [35-37].
Therefore, for quantification, 100 cells at 3 randomly
selected areas were assessed, and the number of cells that
stained positively for c-Myc, cyclin D1, or survivin were
counted.
Statistical analysis
Statistical analysis was performed by one-way ANOVA
and independent-sample T-test using the computer SPSS
software. In all assays, the probability value (P) of < 0.05
was considered statistically significant.
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